Rutgers pioneers a virtual approach to clinical trials, revolutionizing how studies are performed and increasing participant access, leading to stronger scientific results and accelerated treatment
Modest weight loss can lead to meaningful risk reduction in adults with obesity. Although both behavioral economic incentives and environmental change strategies have shown promise for initial weight loss, to date their efficacy alone or in combination have not been compared.
Eating yogurt containing a particular strain of a well-studied probiotic appears to protect against harmful changes in the gut microbiome that are associated with antibiotic administration.
In a research letter in JAMA, physician-researchers at Beth Israel Deaconess Medical Center (BIDMC) found that the vast majority of patients who had a diagnosis of either cognitive impairment, Alzheimer’s disease, or Alzheimer’s disease related disorders, including cardiovascular disease, prior stroke, use of blood thinners, and age over 85 years, would have been excluded them from the aducanumab clinical trials.
Columbia University Irving Medical Center, its Herbert Irving Comprehensive Cancer Center, and Pfizer Inc. have established the Columbia-Pfizer Clinical Trials Diversity Initiative, with the aim of reducing health disparities by increasing the participation of underrepresented minorities in clinical trials and enhancing the diversity of clinical researchers.
From tele-monitoring patients with diabetes to using artificial intelligence to prevent sepsis, the newly launched Center for Health Innovation will seek to develop, test and commercialize technologies that make a real, measurable difference in the lives and wellbeing of patients.
A primary analysis of an experimental HIV vaccine regimen being studied in a high-incidence population of young women in sub-Saharan Africa found the experimental vaccine did not provide sufficient protection against HIV infection.
Researchers reviewed the recent major randomized, double-blind placebo-controlled trials and present an updated meta-analysis of hydroxychloroquine in post-exposure prophylaxis as well as in hospitalized patients.
The first large-scale, long-term trial of a new strategy using combinations of very low-doses in one capsule, has demonstrated significantly improved control of high blood pressure – the leading cause of heart attack and stroke.
A Michigan Medicine physician will co-lead a NIH study of antibody response to an additional dose of the COVID-19 vaccine in people with autoimmune disease. The trial will also assess whether pausing immunosuppressive medication improves immune response to the booster shot.
Hackensack Meridian Hackensack University Medical Center’s Center for Memory Loss & Brain Health has started enrollment for a clinical trial for ATH-1017, an investigational medication for the treatment of mild to moderate Alzheimer’s disease as of August 3, 2021.
Researchers systematically reviewed federally funded cardiovascular disease trials run between 2000 and 2019 to determine whether various recruitment strategies impacted the number of Black participants enrolled.
August 16, 2021 – Chulalongkorn Memorial Hospital, Thai Red Cross Society, and the Vaccine Research Center, Faculty of Medicine, Chulalongkorn University (CVRC) held a press conference on the progress of clinical trials for the Thai “ChulaCov19” mRNA vaccine. The clinical trial (Phase 1) was administered in healthy volunteers who are found to have good immunity after they have been vaccinated. The volunteers’ antibodies have been greatly boosted to prevent the original strain of the virus, and four other variants, namely Alpha, Beta, Gamma, and Delta. Manufacturing and preparation for registration to be used in an emergency are underway.
Hackensack Meridian Hackensack University Medical Center, Center for Memory Loss and Brain Health will be participating in a multicenter clinical trial to study the safety and efficacy of escitalopram, an antidepressant, for the treatment of agitation related to Alzheimer’s disease. This study is sponsored by the National Institute on Aging. Johns Hopkins University is the principal site and Hackensack University Medical Center will begin enrolling patients in the study starting in September 2021.
People who are HIV positive and living in high tuberculosis-transmission regions of the world are much more likely to finish a TB-prevention regimen lasting just three months – half as long as the standard treatment, a large clinical trial in Africa has found.
In a move that will increase access and efficiency of clinical trials for patients with sickle cell disease, UT Southwestern has become a founding member of the new Sickle Cell Disease Clinical Trials Network (SCD CTN) to bring treatments and curative options to people suffering from this potentially life-shortening red blood-cell disorder.
El Cancer Research Institute (CRI), organización sin fines de lucro liderando investigación revolucionaria sobre el poder de nuestro sistema inmunológico para controlar y potencialmente curar todos los tipos de cáncer, ofrecerá su primera Conferencia Virtual CRI de Inmunoterapia para Pacientes con Cáncer 2021 totalmente en español, el 16 de septiembre de 2021, de 2 a 5 p.m. (hora del este).
The Cancer Research Institute (CRI), a nonprofit organization spearheading transformative research to harness the immune system’s power to control and potentially cure all cancers, will offer its first-ever Virtual Cancer Immunotherapy Summit in Spanish on September 16, 2021, 2-5 p.m. ET.
In a real-world trial, a team of clinician-researchers at Beth Israel Deaconess Medical Center have demonstrated that tests of self-collected saliva provided comparable results to tests performed by trained healthcare professionals using NP swabs.
Expert Q&A: Do breakthrough cases mean we will soon need COVID boosters? The extremely contagious Delta variant continues to spread, prompting mask mandates, proof of vaccination, and other measures. Media invited to ask the experts about these and related topics.
The University of Texas MD Anderson Cancer Center has been awarded $12.75 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support basic, clinical, translational and prevention research efforts, including $3 million for a new project to build clinical trial network infrastructure across Texas. MD Anderson also received $3 million for early clinical investigator awards, $750,000 for high-impact, high-risk awards and $6 million for faculty recruitments.
Regardless of COVID vaccination and past infection status, the real measurement of immunity for COVID is the quantity and quality of antibodies each person has.
Researchers at Sinai Hospital in Baltimore are offering a glimpse at how widespread, rapid antibody testing may be conducted in the near future.
This new testing methodology is 99.5% effective, is easy to use, works and looks like a home pregnancy test and yields results in 15-20 minutes allowing for mass testing, particularly amongst children, older adults, and other populations resistant to blood draws.
The researchers say the testing may be the easiest, fastest way to determine if someone needs a booster shot.
In a new National Institutes of Health (NIH) initiative, the University of Miami Miller School of Medicine was selected for a nationwide Liver Cirrhosis Network. Researchers in the network’s 10 academic medical centers will share patient data and launch clinical trials of a class of medications that could prevent progression of the disease, which causes irreversible scarring of the liver, and complications such as liver cancer.
Wellcome Trust has provided a grant to the National University of Singapore to establish the Asian Clinical Research Network to conduct antimicrobial clinical research to develop the most effective ways to treat and prevent life-threatening drug-resistant infections. This will be the first clinical trial network established in Asia focusing on drug-resistant infections.
Combining a histone deacetylase inhibitor drug with immunotherapy agents is safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center, Bloomberg~Kimmel Institute for Cancer Immunotherapy and several other centers including University of Pittsburgh Cancer Institute, Yale Cancer Center and City of Hope in Los Angeles, which participated in study enrollment, and the University of Southern California and University College Cork in Ireland, which collaborated on analysis of the data.
The study enrolled 120 transplant patients between May 25th and June 3rd. None of them had COVID previously and all of them had received two doses of the Moderna vaccine. Half of the participants received a third shot of the vaccine (at the 2-month mark after their second dose) and the other half received placebo.
The primary outcome was based on antibody level greater than 100 U/ml against the spike protein of the virus. In the placebo group - after three doses (where the third dose was placebo), the response rate was only 18% whereas in the Moderna three-dose group, the response rate was 55%.
The study enrolled 120 transplant patients between May 25th and June 3rd. None of them had COVID previously and all of them had received two doses of the Moderna vaccine. Half of the participants received a third shot of the vaccine (at the 2-month mark after their second dose) and the other half received placebo. The primary outcome was based on antibody level greater than 100 U/ml against the spike protein of the virus. In the placebo group - after three doses (where the third dose was placebo), the response rate was only 18% whereas in the Moderna three-dose group, the response rate was 55%.
Building on its success with previous COVID-19 vaccine studies, the University of Kentucky has been selected as a site for a trial to assess dose levels of a Johnson & Johnson booster shot.
Cancer clinical trials (CCTs) provide patients an opportunity to receive experimental drugs, tests, and/or procedures that can lead to remissions. For some, a CCT may seem like their only option. Yet little is known about the experiences of patient participants who withdraw from CCTs.
• Pooled results from phase 3 clinical trials demonstrate that roxadustat is efficacious and may be comparable to placebo in studies done to date for treating anemia in patients with chronic kidney disease who do not require dialysis.
• In a clinical trial of individuals at high risk for developing type 2 diabetes, which is the leading cause of kidney disease, vitamin D supplementation did not have significant effects on kidney health.
• As participants were not selected according to baseline vitamin D levels, investigators cannot exclude a kidney benefit for individuals with vitamin D deficiency.
Scientists at Case Western Reserve University have used Artificial Intelligence (AI) to identify new biomarkers for breast cancer that can predict whether the cancer will return after treatment—and which can be identified from routinely acquired tissue biopsy samples of early-stage breast cancer.
A survey of participants in a clinical trial for CommunityRx, a community resource referral intervention, found that nearly half of users reported sharing their personalized health resources with at least one other person.
The investigators discovered that in moderately ill patients full-dose heparin reduced the need for organ support compared to those who received lower-dose heparin.
DALLAS – August 4, 2021 – Researchers at UT Southwestern announced successful results of a clinical trial for a commonly prescribed weight-loss drug called liraglutide. In adults who are overweight or have obesity combined with high cardiovascular risk, once-daily liraglutide combined with lifestyle interventions significantly lowered two types of fat that have been associated with risk to heart health: visceral fat and ectopic fat.
A clinical trial found liraglutide, an injectable weight loss medication, reduced intra-abdominal and liver fat in participants more than placebo in addition to a low-calorie diet and increased physical activity.
Scientists using the Advanced Photon Source have discovered that a drug used to fight tumors in animals might be effective against many types of coronaviruses, including SARS-CoV-2.
Irvine, Calif., Aug. 2, 2021 — From cutting-edge research for advancing precision medicine to an innovative new effort for improving public water infrastructure to increase conservation, University of California, Irvine scholars, scientists and physicians are blazing new paths to help change the world. And their impact keeps growing.
With overdose rates involving cocaine soaring nearly 27% in 2020, researchers at The University of Texas Health Science Center at Houston (UTHealth) hope that a clinical trial combining a medication approved for the treatment of Type 2 diabetes with cognitive behavioral therapy (CBT) can help prevent relapse in cocaine use disorder patients.
People living in the South, known as the Stroke Belt, are not only at a greater risk of having strokes, but the region is also associated with higher stroke mortality. The link between high blood pressure and stroke is well-known, and lowering blood pressure reduces stroke risk. But how can blood pressure be most effectively managed among stroke survivors, and is the use of telehealth the most effective strategy?
Cardiovascular physicians with UC San Diego Health have joined an international clinical trial utilizing a new Extravascular Implantable Cardioverter-Defibrillator (EV ICD) system to help treat sudden cardiac arrest.
Results from a large phase 3 noninferiority clinical trial definitively showed that vincristine and dexamethasone pulses can be eliminated in patients with low-risk disease. The findings were published today in The Lancet Oncology.
Chula Pharmacy prepares to test “Baiya Vaccine” a Thai vaccine against COVID–19 by “Baiya Phytofarm“, a Chula startup. The vaccines have been produced at the first plant in Asia that manufactures plant–based vaccines for humans. Clinical trials with volunteers and the research for the second–generation vaccine to fight the virus variants are to commence in September 2021.
Individuals with severe tricuspid valve regurgitation, in which the valve between the two right heart chambers closes incorrectly, may be eligible for a new clinical trial to treat the condition.